e15070 Background: Trifluridine/tipiracil (FTD/TPI) was recently approved for the treatment of third-line or later (3L+) metastatic colorectal cancer (mCRC). The objective of this study was to develop a payer-perspective budget impact model to estimate the 1-year budgetary consequences of adding FTD/TPI to a health plan’s formulary when a portion of the eligible mCRC patients who are currently treated with regorafenib are treated with FTD/TPI. Methods: The baseline annual budget for treating 3L+ mCRC patients, including pharmacy, administration, monitoring, and adverse-event (AE) costs, and excluding FTD/TPI, was estimated. Pharmacy costs were calculated using wholesale acquisition costs, and all other costs, AE rates, dosing administration, and monitoring guidelines were obtained from publically available sources. The model assumes that all treatment costs were incurred over 1 year, all AEs were mutually exclusive, and 30% of serious AEs (grades 3 and 4) were treated on an inpatient basis. Medication costs associated with outpatient AE management were not included. Using a regorafenib replacement strategy which pulls FTD/TPI market share from regorafenib, the projected annual budget was calculated assuming 30.5% adoption by FTD/TPI. Results: Of the hypothetical population of 1 million, approximately 107 were mCRC patients eligible for receiving 3L+ treatment. A net saving of $230,949 (−6.3%) in total costs was achieved when FTD/TPI therapy was included on total costs of $3,412,713, with the greatest savings in medication (−7.7%) and AE management costs (−0.3%). The reduction in cost per treated patient per year was $2150.12, and the net budget impact was −$0.02 (−6.3%) per member per month. Conclusions: Inclusion of FTD/TPI therapy in the model resulted in net savings in medication, AE management, and total costs, and costs per treated patient per year. These data suggest potential savings if FTD/TPI is added to a health plan formulary for the 3L+ treatment of mCRC patients. Sponsorship: Taiho Oncology, Inc. Editorial Assistance: Complete HealthVizion.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.